Disease or Syndrome – Page 55

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

7 months ago talkbio0Tagged Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

7 months ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce

7 months ago talkbio0Tagged Advocacy, CHARGE Syndrome, employee layoffs, federal, Force, layoffs, Mediation, public health medicine (field), reduction in force, restructuring, Union, United States Food and Drug Administration

FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy

Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision

7 months ago talkbio0Tagged Safety, VERVE-102

VERVE-102, Safety

As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay

7 months ago talkbio0Tagged alternatives, Clinical Trials, gene therapy, Hemgenix, HYMPAVZI, Pfizer, SMPX gene

Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials

Tome Bio founders wrangle jumping genes to create new programmable gene insertion tool

7 months ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PGI, Retrotransposons, Technology

PGI, Technology, Retrotransposons, Clustered Regularly Interspaced Short Palindromic Repeats

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

7 months ago talkbio0Tagged biotech, Clinical Trial Failures, Cost savings programs, Glycogen storage disease type II, Industry, Opthea layoffs, Pfizer, Pfizer staff, Pharma, restructuring

Opthea layoffs 2025 , Pfizer staff reduction , Biotech job cuts , Pharma restructuring , Clinical trial failures , Wet AMD treatment , Cost savings programs , Pfizer San Diego layoffs , Biotech industry challenges

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

7 months ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil

7 months ago talkbio0Tagged Brazil, Claros facility, Diabetes, Glucagon-Like Peptide 1, Investments, Montes, Nordisk, Obesity, Ozempic, pharmaceutical manufacturing, production, Wegovy

Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing

Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling

7 months ago talkbio0Tagged Administration occupational activities, Administrative Procedure Act, appeal, CHARGE Syndrome, federal judge, Health Policy, Indirect, injunction, Legal, Medical Research activity, NIH Mouse, Permanent, research, Transplant Registry Unified Management Program, U.S., United States

NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.